CA2373178C - Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires - Google Patents

Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires Download PDF

Info

Publication number
CA2373178C
CA2373178C CA2373178A CA2373178A CA2373178C CA 2373178 C CA2373178 C CA 2373178C CA 2373178 A CA2373178 A CA 2373178A CA 2373178 A CA2373178 A CA 2373178A CA 2373178 C CA2373178 C CA 2373178C
Authority
CA
Canada
Prior art keywords
group
inhibitor
pharmaceutically acceptable
carboxylic acid
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2373178A
Other languages
English (en)
Other versions
CA2373178A1 (fr
Inventor
Eugene De Juan Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Medicine of Johns Hopkins University
Original Assignee
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School of Medicine of Johns Hopkins University filed Critical School of Medicine of Johns Hopkins University
Publication of CA2373178A1 publication Critical patent/CA2373178A1/fr
Application granted granted Critical
Publication of CA2373178C publication Critical patent/CA2373178C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne un procédé de traitement prophylactique et thérapeutique pour la dégénérescence maculaire liée au vieillissement, ainsi que des procédés de traitement prophylactique et thérapeutique pour les complications exsudatives et atrophiques de ladite dégénérescence. Ces procédés consistent à administrer un inhibiteur de trajet de protéine tyrosine kinase à un animal, du type mammifère, en particulier à un être humain, en quantité suffisante pour les besoins du traitement prophylactique ou thérapeutique de la dégénérescence ou des complications considérées, respectivement. L'invention concerne en outre un procédé de traitement prophylactique et thérapeutique pour la dégénérescence rétinienne, un procédé de traitement prophylactique et thérapeutique pour la dégénérescence choroïdienne, et un procédé de traitement prophylactique et thérapeutique pour l'épaississement de la membrane de Bruch. Ces procédés consistent à administrer un inhibiteur de trajet de protéine tyrosine kinase à un animal, du type mammifère, en particulier à un être humain, en quantité suffisante pour les besoins du traitement prophylactique ou thérapeutique de la dégénérescence maculaire, rétinienne ou choroïdienne, ou bien de l'épaississement de la membrane de Bruch, respectivement. De préférence, cet inhibiteur est de la génistéine ou bien un analogue ou un promédicament correspondant, ou encore un sel pharmaceutiquement acceptable de l'un quelconque de ces produits.
CA2373178A 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires Expired - Fee Related CA2373178C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US60/133,112 1999-05-07
US35044099A 1999-07-09 1999-07-09
US09/350,440 1999-07-09
PCT/US2000/012339 WO2000067738A2 (fr) 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires

Publications (2)

Publication Number Publication Date
CA2373178A1 CA2373178A1 (fr) 2000-11-16
CA2373178C true CA2373178C (fr) 2013-07-02

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2373178A Expired - Fee Related CA2373178C (fr) 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires

Country Status (6)

Country Link
EP (1) EP1178791A2 (fr)
JP (1) JP4920134B2 (fr)
AU (1) AU774495B2 (fr)
CA (1) CA2373178C (fr)
MX (1) MXPA01011344A (fr)
WO (1) WO2000067738A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
US20210038077A1 (en) * 2018-01-25 2021-02-11 Osaka University Method for detecting stressed state and stress detection apparatus
CN114931574A (zh) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 一种铁死亡抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
DE69740095D1 (de) * 1996-11-05 2011-02-17 Childrens Medical Center Thalidomide und Dexamethason für die Behandlung von Tumors
EP0973533A4 (fr) * 1997-03-14 2001-03-14 Univ California Methodes d'inhibition de cytotoxicite bacterienne
EP1017682A4 (fr) * 1997-09-26 2000-11-08 Merck & Co Inc Nouveaux inhibiteurs de l'angiogenese
EP1061913B1 (fr) * 1998-03-13 2007-06-27 The Johns Hopkins University School Of Medicine Traitement de la retinopathie diabetique au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine

Also Published As

Publication number Publication date
MXPA01011344A (es) 2004-06-03
WO2000067738A3 (fr) 2001-08-23
AU774495B2 (en) 2004-07-01
WO2000067738A2 (fr) 2000-11-16
JP2002544159A (ja) 2002-12-24
AU4988400A (en) 2000-11-21
JP4920134B2 (ja) 2012-04-18
EP1178791A2 (fr) 2002-02-13
CA2373178A1 (fr) 2000-11-16

Similar Documents

Publication Publication Date Title
US6399655B1 (en) Method for the prophylactic treatment of cataracts
US5919813A (en) Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
EP1061913B1 (fr) Traitement de la retinopathie diabetique au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine
US6028099A (en) Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
US5980929A (en) Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
AU2013259526B2 (en) New methods
CA2554679C (fr) Agent prophylactique ou therapeutique pour la maculopathie diabetique
CA2373178C (fr) Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires
US20180071275A1 (en) Treatment of ocular inflammatory diseases using laquinimod
US20240009168A1 (en) Compositions for treating dry age-related macular degeneration (amd)
JP7436067B2 (ja) ナノ低分子ペプチドｆｇ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用
US20030181510A1 (en) Inhibition of muscle regeneration following myectomy
KR19980063712A (ko) 망막증의 치료에 유용한 저급 알카노일 ｌ-카르니틴
JP7090336B2 (ja) Ｎａｄ関連代謝産物の利用
US11717513B2 (en) Mirabegron for the treatment of retinal diseases
US6852688B2 (en) Compositions for treating diabetic retinopathy and methods of using same
US6248759B1 (en) Method for treatment of light-injured retinal degeneration disease
CA2575850A1 (fr) Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine
KR101327663B1 (ko) 안지오제닌의 신규 용도
CN116898800A (zh) 无防腐剂的眼科药物乳剂及其应用
MXPA00008988A (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160505